Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes.

Creative Commons License

Komsuoglu Celikyurt I., MUTLU O., ULAK G., Uyar E., Bektaş E., YILDIZ AKAR F., ...More

Medical science monitor basic research, vol.20, pp.112-7, 2014 (Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20
  • Publication Date: 2014
  • Doi Number: 10.12659/msmbr.891168
  • Journal Name: Medical science monitor basic research
  • Journal Indexes: Scopus
  • Page Numbers: pp.112-7
  • Keywords: Anti-Anxiety Agents, Behavior, Animal, Depression, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, GLUCAGON-LIKE PEPTIDE-1, SYNAPTIC PLASTICITY, DEPRESSION, PREVALENCE, ANXIETY, DISEASE
  • Kocaeli University Affiliated: Yes


Background: Comorbid neurobehavioral disturbances and type-2 diabetes mellitus (T2DM) warrant immediate research attention. Exenatide, which is a potent and selective agonist for the glucagon-like peptide-1 (GLP-1), is used in the treatment of T2DM. Exenatide displays a multitude of effects in the central nervous system. The aim of this study was to investigate the anxiolytic- and antidepressant-like effects and analgesic effects of exenatide in a type-2 diabetic mouse model.